ASAnju Sharma

Anju Sharma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anju Sharma has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Aztreonam–Avibactam Susceptibility and Genomics of NDM-Producing Escherichia coli in Pediatric Patients from Gaza and Qatar

    by Andrés Pérez-López, Mohammed Suleiman, Elaine Mariano, Diyna Altrmanini, Humna Shafaq, Thabisile Xaba, Anju Sharma, Muhammad Iqbal, Tamara Elshareif, Hiam Chemaitelly, et al.

    Background: Aztreonam–avibactam (ATM/AVI) emerges as a promising treatment for pediatric infections caused by New Delhi metallo-beta-lactamase (NDM)-producing Escherichia coli once approved for children aged ≤18 years. Methods: We assessed in vitro susceptibility to ATM/AVI and characterized the molecular resistance mechanisms in NDM-producing E. coli recovered from admission rectal screening swabs of war-affected Palestinian children (December 2023–July 2024) and children in Sidra Medicine’s catchment population in Doha (January 2022–December 2025). Minimum inhibitory concentrations (MICs) were determined using the MIC Test Strip method and interpreted according to the European Committee on Antimicrobial Susceptibility Testing breakpoints. Penicillin-binding protein 3 (PBP3) insertions and the co-production of CMY-type plasmid-mediated AmpC beta-lactamases (pAmpC) were characterized by short-read whole-genome sequencing. Linear regression estimated mean differences in log2-transformed MICs by PBP3 insertion and CMY status. Results: A total of 74 non-duplicate NDM-producing E. coli isolates were analyzed, of which 69 (93.2%) produced NDM-5. Overall, 18 (24.3%) isolates exhibited resistance to ATM/AVI (MIC > 4 mg/L). Sixty-six (89.2%) isolates harbored PBP3 insertions, comprising YRIN (48 isolates; 64.9%), mainly detected in ST167, and YRIK (18 isolates; 24.3%), mainly detected in ST405. CMY-42 (17 isolates) and CMY-145 (eight isolates) were exclusively identified in isolates concurrently harboring PBP3 insertions. ATM/AVI log2 MICs were significantly higher in isolates harboring PBP3 insertions, particularly YRIK, and increased further when combined with CMY-42 or CMY-145. Conclusions: Our study reveals a high proportion of NDM-producing E. coli belonging to high-risk clones harboring PBP3 mutations, either alone or in combination with CMY-type pAmpC, driving substantial increases in ATM/AVI MICs across two distinct Middle Eastern pediatric cohorts. Large-scale regional genomic surveillance is needed to determine the extent of convergent resistance mechanisms associated with reduced susceptibility to ATM/AVI and other newer β-lactams targeting PBP3.

  • Open Access

    Elaeagnus angustifolia Plant Extract Inhibits Epithelial-Mesenchymal Transition and Induces Apoptosis via HER2 Inactivation and JNK Pathway in HER2-Positive Breast Cancer Cells

    by Ayesha Jabeen, Anju Sharma, Ishita Gupta, Hadeel Kheraldine, Semir Vranic, Ala-Eddin Al Moustafa, Halema F. Al Farsi

    Elaeagnus angustifolia (EA) is a medicinal plant used for treating several human diseases in the Middle East. Meanwhile, the outcome of EA extract on HER2-positive breast cancer remains nascent. Thus, we herein investigated the effects of the aqueous EA extract obtained from the flowers of EA on two HER2-positive breast cancer cell lines, SKBR3 and ZR75-1. Our data revealed that EA extract inhibits cell proliferation and deregulates cell-cycle progression of these two cancer cell lines. EA extract also prevents the progression of epithelial-mesenchymal transition (EMT), an important event for cancer invasion and metastasis; this is accompanied by upregulations of E-cadherin and β-catenin, in addition to downregulations of vimentin and fascin, which are major markers of EMT. Thus, EA extract causes a drastic decrease in cell invasion ability of SKBR3 and ZR75-1 cancer cells. Additionally, we found that EA extract inhibits colony formation of both cell lines in comparison with their matched control. The molecular pathway analysis of HER2 and JNK1/2/3 of EA extract exposed cells revealed that it can block HER2 and JNK1/2/3 activities, which could be the major molecular pathway behind these events. Our findings implicate that EA extract may possess chemo-preventive effects against HER2-positive breast cancer via HER2 inactivation and specifically JNK1/2/3 signaling pathways.


  • Open Access

    Investigating Coronary Artery Disease methylome through targeted bisulfite sequencing

    by Subhoshree Ghose, Sourav Ghosh, Vinay Singh Tanwar, Priya Tolani, Anju Sharma, Nitin Bhardwaj, Kv Shamsudheen, Ankit Verma, Rijith Jayarajan, Sridhar Sivasubbu, et al.

    Background: Gene environment interactions leading to epigenetic alterations play pivotal role in the pathogenesis of Coronary Artery Disease (CAD). Altered DNA methylation is one such epigenetic factor that could lead to altered disease etiology. In this study, we comprehensively identified methylation sites in several genes that have been previously associated with young CAD patients. Methods: The study population consisted of 42 healthy controls and 33 young CAD patients (age group < 50 years). We performed targeted bisulfite sequencing of promoter as well as genic regions of several genes in various pathways like cholesterol synthesis and metabolism, endothelial dysfunction, apoptosis, which are implicated in the development of CAD. Results: We observed that the genes like GALNT2, HMGCR were hypermethylated in the promoter whereas LDLR gene promoter was hypomethylated indicating that intracellular LDL uptake was higher in CAD patients. Although APOA1 did not show significant change in methylation but APOC3 and APOA5 showed variation in methylation in promoter and exonic regions. Glucokinase ( GCK ) and endothelial nitric oxide synthase 3 (NOS3) were hyper methylated in the promoter. Genes involved in apoptosis (BAX/BCL2/AKT2) and inflammation ( PHACTR1/LCK ) also showed differential methylation between controls and CAD patients. Conclusions: This study is unique because it highlights important gene methylation alterations which might predict the risk of young CAD in Indian population. Large scale studies in different populations would be important for validating our findings and understanding the epigenetic events associated with CAD.